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WE DANCE ROUND IN A RING AND SUPPOSE, BUT 
THE SECRET SITS IN THE MIDDLE AND KNOWS. 
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Here we highlight current data of the involvement of cholesterol, 
lipoproteins and lipoprotein receptors in the neuronal 
development and of neurotrophic factors in the lipid and 
glucose metabolism. We term these interactions neuro-
lipidology. And argue that in addition to its implication in 
neurodegenerative diseases such as Alzheimer's disease (1), 
neurolipidology may have wide-ranging potential within a 
variety of nonneuronal fields, including cardiovascular disease, 
particularly, atherosclerosis and related disorders. 
Emerging evidence shows that neurotrophic factors, such as 
nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), leukemia inhibitory factor (LIF), 
and hepatocyte growth factor are involved in the process of 
atherogenesis (2, this volume of Biomedical Reviews). Because 
altered plasma concentrations of low density lipoprotein (LDL), 
very low density lipoprotein (VLDL), and high density 
lipoprotein (HDL) are among the principle players in the process 
of atherogenesis, they have been considered by many authors to 
act mainly on various cells of the artery wall. However, it appears to 
be much more than that. Indeed, it is known that LDL 
receptors (LDLR) can bind not only lipoproteins but also other 
ligands, and thereby involved in processes not solely related to 
lipoprotein internalization and metabolism. More recently, the 
neuronal development becomes one remarkable example of 
that. Likewise, in addition to their effects on the lipid and 
glucose metabolism of neuronal cells, as first demon-strated for 
NGF by Levi-Montalcini, neurotrophic factors may also 
exert such eff ects on nonneuronal cells, including adipocytes, 
hepatocytes, and pancreatic beta cells. 
CHOLESTEROL, LIPOPROTEINS AND LIPOPROTEIN 
RECEPTORS AMD NEURONAL DEVELOPMENT 
Although cholesterol has long been known to be an essential 
component of plasma membrane, recent studies have 
suggested that cholesterol plays an essential role during the 
development of nervous system (3). Likewise, accumulating 
evidence suggests that membrane cholesterol and sphin-
golipids cluster to form functional rafts that move within the 
fluid bilayer and influence receptor-mediated signal trans-
duction and membrane trafficking (4,5). 
Since first demonstrated by Brown and Goldstein, the 
importance of the LDLR in the regulation of cholesterol 
homeostasis has been studied intensively by virtue of its 
malfunction being causally related to atherosclerosis. Other 
members of the mammalian LDLR gene family are: LDLR-related 
protein (LRP), very low density lipoprotein receptor (VLDLR), 
apolipoprotein E receptor 2 (apoER2), and megalin (6 and Refs 
therein). Further, cubilin, the intrinsic factor-B 12 receptor, also 
exerts an extraintestinal function, facilitating endocytosis of 
HDL (7). Most of these receptors bind and import not only 
lipoproteins but multiple ligands, such as amyloid precursor 
protein and various proteases and their inhibitors. Specifically, 
the extracellular matrix protein reelin binds the ectodomain of 
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both VLDLR and apoER2, and thereby is critically involved in 
the neurotopogenesis in the brain (6,8,9). Furthermore, cubilin, 
megalin, and p39 receptor-associated protein also play important 
roles in the biology of neurons. In addition, cholesterol can 
also affect neuronal development (3,10) and, curiously 
enough, statins, a group of HMG-CoA inhibitors that are widely 
used in atherosclerosis therapy, exhibit neuroprotective 
properties (11). 
While numerous studies demonstrated that perivascular 
sympathetic nerves are associated with spontaneously hyper 
tensive rats, their role in atherosclerotic lesion formation is 
largely ignored despite several studies suggest an inverse 
relation between the density of these nerves and the deve 
lopment of atherosclerosis (2). Recently, gene knockout and 
targeted overexpression have been used to generate models of 
disordered lipoprotein metabolism and atherosclerosis. The 
most extensively characterized of these models are apoE and 
LDLR knockout mice. ApoE-deficient mice (12) and cholesterol- 
fed rabbits/rats (13,14) also develop neuronal abnormalities. 
Principally, the neuronal abnormalities related to deficiency of 
lipoprotein receptors, as well as neuropathies related to dys- 
lipidemia, could also be associated with low levels of neuro- 
trophic factors, as shown for NGF in diabetic neuropathy (15). 
Thus, the question remains as to whether lipoproteins and/or 
their receptors might affect the neuronal development through 
alterations in the secretion and/or signaling of neurotrophic 
factors. For example, caveolin, a coating protein of endocytic, 
plasma membrane cholesterol-dependent, organelle called 
caveolae, regulates neurotrophin signaling (16), whereas 
caveolin (17) and LRP (18) expressions are upregulated by NGF. 
And BDNF regulates reelin expression in neuronal deve 
lopment (19). Nonetheless, genetically-modified models of 
disordered lipoprotein metabolism could be further examined, 
in order to see whether nerves, including perivascular sym 
pathetic nerves, are affected. These considerations taken 
together suggest that in cardiovascular research, the targets 
for lipid/glucose metabolism-associated molecules should no 
longer be considered only vascular wall cells but also peri 
vascular nerves. . 
LDL levels (24), and therby inhibits atherosclerosis 
development (25). It is also noteworthy that (i) BDNF (26) and 
mast cells (27), known to secrete multiple neurotrophic factors, 
are implicated in the glucose and lipid metabolism, and (//) 
pancreatic beta cells secrete and respond to NGF (28). These 
findings suggest neurotrophin-mediated metabotrophic 
functions, thus further implicate these molecules in 
cardiovascular disease and related disorders, such as 
metabolic syndrome. 
As outlined above, there are certain interactions between 
NGF and caveolin (16,17). An additional comment about 
caveolin needs a special attention. First, both the structure and 
the function of caveolae are crucially dependent on plasma 
membrane cholesterol (4,5). Second, oxidation of cholesterol 
leads to migration of caveolin, from the plasma membrane to 
the Golgi complex, and hence inhibition of caveolae-mediated 
process called potocytosis (4,5). Third, folate is one of the 
principle molecules that is imported by caveolae (4,5). Fourth, 
high plasma levels of homocysteine are among the known risk 
factors for atherosclerosis (29); since homocysteine metabolism is 
closely linked to that of vitamin B12, one may keep in mind that 
an important function of cubilin (7) is the import of vitamin B12. 
All these possibilities could be further explored, using 
multiple transgenic animal models of neurotrophic factors/ 
receptors, in order to see whether the lipid, glucose, and 
homocysteine metabolism are also affected. 
,,SHALL WE DANCE": A CHALLENGE OF FIELD MIXING 
The findings presented here suggest a complex arrangement 
between cholesterol, lipoproteins/receptors, nerves, and 
neurotrophic factors and the pathobiolgy of cardiovascular 
disease. Mixing fields is a challenge that promises high rewards, 
for both scientists and science alike. Metaphorically, as in the 
song "Shall we dance", from the American movie "Anna and 
the King", our hypothesis suggests an invitation for vascular 
biology and neurobiology to dance round in a ring of 
neurolipidology, in the study of atherosclerosis and related 
disorders. 
  
NEUROTROPHIC FACTORS AND LIPID AND GLUCOSE 
METABOLISM 
Recent years witnessed an increased knowledge of the roles 
played-by neurotrophic factors in the biology of a large number 
of nonneuronal cells. The potential role of neurotrophic factors in 
the lipid and glucose metabolism of nonneuronal cells has just 
recently emerged. For example, NGF, which shares a striking 
structural homology with proinsulin (20), and LIF exert effects on 
the lipid metabolism in both adipocytes and hepatocytes 
(21,22). Similarly, LIF and ciliary neurotrophic factor stimulate 
hepatic triglyceride secretion (23), and LIF increases LDLR 
expression in liver cells and decreases serum cholesterol and 
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